GI Pancreatic - Metastatic

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

Second Line Treatment for Advanced or Metastatic Pancreatic Cancer

Third Line Treatment for Advanced or Metastatic Pancreatic Cancer

Localized

NeoAdjuvant

Adjuvant

First Line Treatment for Advanced or Metastatic Pancreatic Cancer

IRB#17751
SMMART Trial:
Stand up to Cancer: Study of the Safety, Immunopharmacodynamics and Anti-tumor Activity of Ibrutinib Combined with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Adenocarcinoma

IRB#15304
AM0010-301: A Randomized Phase 3 Study of AM0010 in Combination with FOLFOX Compared with FOLFOX Alone as Second-line Therapy in Patients with Metastatic Pancreatic Cancer that has Progressed During or Following a First-Line Gemcitabine Containing Regimen

IRB#16609
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

IRB#17094
SMMART Trial: A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)

Metastatic

In Development

Open for Enrollment

Enrollment on Hold

http://www.ohsu.edu/research/rda/so/knight.php

1/29/2018